Lyell Immunopharma, Inc. (LYEL) Stock Price & Analysis
Lyell Immunopharma, Inc. (LYEL) rose 3.17% to USD 12.7 as of June 10, 2026 at 00:50 UTC, according to Nexqual real-time market data.
LYEL last closed at USD 12.31; the session ranged USD 12.17–13.03 on volume of 98,683 shares. Market capitalization is $296.34M, with a 52-week range of USD 8.46–45 (NMS). Source: Nexqual, June 10, 2026 at 00:50 UTC.
Key Statistics (as of June 10, 2026 at 00:50 UTC)
| Price | USD 12.7 |
|---|---|
| Change | ▲ 3.17% (up) |
| Previous Close | USD 12.31 |
| Open | USD 12.5 |
| Day Range | USD 12.17 – 13.03 |
| 52-Week Range | USD 8.46 – 45 |
| Volume | 98,683 shares |
| Market Cap | $296.34M |
| Exchange | NMS |
Technical Analysis (LYEL)
Nexqual's technical model rates LYEL "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:50 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.04 (oversold) |
| vs SMA50 | Below (USD 19.63) |
| MACD | -2.04 (negative) |
Analyst Ratings (LYEL)
Wall Street analysts rate LYEL "Buy" based on 6 analysts, with a mean price target of USD 37.17 (range USD 12–49), per Nexqual as of June 10, 2026 at 00:50 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 37.17 |
| High Target | USD 49 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 5 / 0 / 1 |
Earnings (LYEL)
| Next Earnings Date | 2026-05-15 |
|---|---|
| Revenue Estimate | $4,600 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.1 vs est -2.36 ▲ beat |
| 2025-12-31 | USD -7.68 vs est -2.23 ▼ miss |
| 2025-09-30 | USD -2.13 vs est -2.64 ▲ beat |
| 2025-06-30 | USD -2.89 vs est -3.58 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financials & Fundamentals (LYEL)
| Total Revenue | $31,000 |
|---|---|
| Revenue Growth (YoY) | -71.40% |
| Gross Margin | +100.00% |
| Operating Margin | -2213050.00% |
| Profit Margin | +0.00% |
| ROE | -80.76% |
| Debt / Equity | 17.85 |
| Current Ratio | 7.24 |
| Total Cash | $254.02M |
| Total Debt | $48.85M |
| Free Cash Flow | $-77.38M |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financial Health Score (LYEL)
Nexqual rates Lyell Immunopharma, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:50 UTC.
| Growth | Critical — Revenue -41% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $254M cash vs $49M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$77M, burning cash |
| Efficiency | Critical — ROE -81%, ROA -29.9% |
Ownership (LYEL)
| Insider Ownership | +35.41% |
|---|---|
| Institutional Ownership | +58.33% |
| Shares Outstanding | 23.33M |
| Float | 10.39M |
| Short % of Float | +6.83% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Leadership (LYEL)
Lyell Immunopharma, Inc. is led by Lynn Seely (age 66), Principal Executive Officer, President, CEO & Director, per Nexqual as of June 10, 2026 at 00:50 UTC.
| Principal Executive Officer, President, CEO & Director | Lynn Seely (age 66) |
|---|---|
| Founder & Executive Chairman | Richard D. Klausner (age 73) |
| Chief Operating Officer | Stephen J. Hill (age 54) |
| Chief Scientific Officer | Gary K. Lee (age 48) |
| Principal Financial Officer, CFO & Chief Business Officer | Smital Shah (age 49) |
Major Backers & Investors (LYEL)
Notable institutional backers of Lyell Immunopharma, Inc. include Arch Venture Management, Llc, GSK plc, Foresite Capital Management IV, LLC, according to Nexqual as of June 10, 2026 at 00:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Arch Venture Management, Llc | 13.92% |
| GSK plc | 6.48% |
| Foresite Capital Management IV, LLC | 5.47% |
| Mwg Caph Ltd | 4.32% |
| Orland Properties Ltd. | 3.23% |
| Decheng Capital LLC | 2.97% |
| Almitas Capital LLC | 2.48% |
| Millennium Management | 1.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.18% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
From Lyell Immunopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Our research scientists are also developing next-generation CAR T-cell product candidates for additional solid tumor indications enhanced with our anti-exhaustion and additional arming technologies and manufactured with our proprietary protocols.
- We continue to invest in earlier stage cell therapy research and development utilizing our proprietary technologies.
- Epi-R Manufacturing Protocol Epi‑R is our proprietary ex vivo manufacturing protocol that is designed to generate populations of stemlike T cells with reduced exhaustion and improved proliferation and antitumor activity.
- Our nonclinical research activities explore stacking our proprietary anti-exhaustion technologies with these additional approaches via the expression of novel chimeric proteins and vector design to generate fully-armed CAR T-cell product candidates.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | USD 2.21 | ▲ 3.76% |
| ERAS | Erasca, Inc. | USD 13.41 | ▲ 12.03% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 16.61 | ▲ 1.47% |
| TYRA | Tyra Biosciences, Inc. | USD 25.94 | ▼ 2.63% |
| PMVP | PMV Pharmaceuticals, Inc. | USD 1.05 | ▼ 6.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:50 UTC. This page is informational and not investment advice.